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Summary
 
The establishment of culture conditions that selectively support hematopoietic stem cells is an
important goal of hematology. In this study, we investigated the possibility of using for this
purpose a defined medium, mSFO2, which was developed for stromal cell–dependent bone
marrow cultures. We found that a combination of epidermal growth factor (EGF), the OP9
stromal cell line, which lacks macrophage colony-stimulating factor, recombinant stem cell fac-
tor, and the chemically defined medium mSFO2 provides a microenvironment where c-Kit
 
1
 
Thy-1
 
1
 
/lo
 
 Mac-1
 
1
 
/lo
 
 B220
 
2
 
 TER119
 
2
 
 common
 
b
 
1
 
 IL-2R
 
g
 
1
 
 gp130
 
1
 
 cells are selectively propa-
gated from normal, unfractionated bone marrow cells. This cell population produced an in
vitro colony at a very high efficiency (50%), whereas it has only limited proliferative ability in
the irradiated recipient. Thus, the cells selected in this culture condition might represent col-
ony-forming units in culture (CFU-c) with short-term reconstituting ability. Transferring this
cell population into medium containing differentiation signals resulted in the rapid production
of mature myelomonocytic and B cell lineages in vitro and in vivo. The fact that a similar cul-
ture condition was created by erb-B2–transduced OP9 in the absence of EGF indicated that
EGF exerts its effect by acting on OP9 rather than directly on CFU-c. These results suggested
that the balance between self-renewal and differentiation of CFU-c can be regulated by extra-
cellular signals.
 
A
 
n important goal of experimental hematology is to
manipulate the proliferation and differentiation of the
normal hematopoietic stem cells. As an approach to this
end, extensive efforts have been made to establish cultures
where the growth of hematopoietic stem cells is main-
tained. The stromal cell–dependent, long-term bone mar-
row (BM)
 
1
 
 culture developed by Dexter and his colleagues
(1) has been the most successful means of maintaining he-
matopoietic stem cells in vitro. Although the sustained self-
renewal of the multipotent stem cells is supported in this
system, concomitant terminal differentiation into the my-
elomonocytic cell lineage does occur. As a result of this dif-
ferentiation in culture, a minor population of multipotent
stem cells persists, and the production of hematopoietic
cells eventually ceases because of the imbalance between
self-renewal and differentiation of the stem cells. Thus, any
method that alters this balance in favor for self-renewal
might result in a culture where hematopoietic progenitors
are spontaneously enriched. In fact, this has been attained
in cultured embryonic stem cells using leukemia inhibitory
factor as a molecular cue (2, 3).
One way to change the balance in favor of self-renewal
is to block the intracellular machinery that drives the he-
matopoietic stem cell to differentiate. However, once the
intracellular machinery for cell differentiation is artificially
locked, it is difficult to release it physiologically. Alterna-
tively, extensive attempts have been made to determine the
growth factor combination that allows the proliferation of
stem cells while arresting cell differentiation (4–13), as leu-
kemia inhibitory factor does to the embryonic stem cells.
Moreover, a number of untransformed stem cell lines,
some of which have been claimed to give rise to the whole
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range of hematopoietic cell lineage, have been described
(14–16). However, those cell lines have not been generally
applied for two main reasons. Most, if not all, of these stem
cell lines tend to lose sensitivity to differentiation signals,
though a small proportion of them may differentiate upon
stimulation either in vitro or in vivo. Moreover, it is usu-
ally difficult to reproduce the culture conditions described
in the original reports because of the presence of chemi-
cally undefined ingredients in the media.
In this study, we investigated ways to overcome this
problem. We reduced the differentiation factors present in
ordinal long-term BM culture using the defined culture
medium mSFO2, which contains transferrin and insulin as
the only protein components, as well as the macrophage
CSF (M-CSF)–negative stromal cell clone OP9.
 
Materials and Methods
 
Cell Preparation.
 
The stomal cell line OP9 was maintained in
 
a
 
-MEM (GIBCO BRL, Gaithersburg, MD) containing 20%
FCS (lot No. 1M1250; BioWhittaker, Walkersville, MD), as re-
ported (17). The subline OP9/erbB2 that can survive in serum-
free media without external growth factors was generated by
means of calcium phosphate transfection performed essentially as
reported (18). Briefly, exponentially growing OP9 cells were
seeded at a density of 5 
 
3
 
 10
 
5
 
 cells on 10-cm tissue culture plates
in 
 
a
 
-MEM with 20% FCS 1 d before transfection. On the day of
transfection, calcium phosphate DNA solution was added drop-
wise into the medium, and the cells were incubated for 24 h in a
37
 
8
 
C, 5% CO
 
2
 
 incubator. The OP9 cells were transformed by
cotransfection with the pSV2erbB2VE plasmid containing the
constitutive active phosphorylation site of erbB2 (19–21) in the
cytoplasmic domain (a gift from T. Yamamoto, Institute of Med-
ical Science, University of Tokyo, Tokyo, Japan), as well as the
pSV2
 
bsr
 
 plasmid vector (Funakoshi Co., Tokyo, Japan) containing
the resistance gene for blasticidin S hydrochloride (Funakoshi Co.).
BM cells harvested from normal C57BL/6 mice were sus-
pended in RPMI 1640 medium (GIBCO BRL) with 10% FCS
and passed through Sephadex G-10 (Pharmacia , Uppsala, Swe-
den) twice to deplete stromal cells and macrophages (22, 23).
Stromal cell–depleted BM cells (10
 
5
 
) were seeded onto OP9 stro-
mal cells under various conditions: in 3 ml of RPMI 1640 con-
taining 10% FCS and 0.1% BSA, or in 3 ml of mSFO2 supple-
mented with either recombinant (r) epidermal growth factor
(EGF; 30 ng/ml; Peprotech Inc., Rocky Hill, NJ) or recombi-
nant basic fibroblast growth factor (rbFGF, 10 ng/ml; GIBCO
BRL) with or without recombinant stem cell factor (rSCF; 100
ng/ml; reference 24) on PRIMARIA culture plates measuring
3.5 cm in diameter (Becton Dickinson Labware, Lincoln Park,
NJ). The concentration of SCF was decided based on a previous
report (13). We omitted 2-ME from all conditions. To remove
the effect of serum used for maintaining OP9 cells, confluent
OP9 cells were cultured in mSFO2 medium containing EGF or
bFGF for 5–7 d before seeding BM cells. To initiate BM culture,
all the medium in the culture dish was removed, and BM cells
were plated in the presence of EGF or bFGF. 7–10 d later, cul-
tured BM cells were harvested by pipetting, and 2 
 
3
 
 10
 
4
 
 of them
were replated onto fresh OP9 stromal layers that had been pre-
pared under the same conditions. Subsequently, the passage of the
growing BM cells was repeated in the same manner when the
cells became confluent. BM culture on the erbB2/OP9 stromal
cell layer was initiated and maintained in the same manner, ex-
cept that EGF and bFGF were omitted from the medium.
 
Antibody and Flow Cytometry.
 
The mAbs used in immunoflu-
orescence staining for lineage markers were Mac-1 (M1/70),
B220 (RA3-6B2), anti-CD4 (GK1.5), anti-CD8 (53-6.72), and
TER119 (erythroid lineage marker; 25). THY1 (Thy1.2), ACK4
(anti–c-Kit; 26, 27), A7R (anti–IL-7 receptor; 28), AFS98 (anti–
c-Fms; 29), GP130 (anti-gp130, a gift from Dr. T. Taga, Osaka
University, Osaka, Japan; references 30–33), AIC2B (anti–com-
mon 
 
b
 
 chain for IL-3, -5, GM-CSF, a gift from Dr. S. Yonehara,
Kyoto University, Kyoto, Japan; references 34, 35), and TUGm3
(anti–common 
 
g
 
 chain for IL-2, -4, and -7 a gift from Dr. K.
Sugamura, Tohoku University, Sendai, Japan; references 36, 37)
were also applied. All mAbs were purified and conjugated with
FITC or biotin. Biotinylated antibodies were visualized with PE-
conjugated streptavidin (GIBCO BRL) or FITC-conjugated
streptavidin (Sigma Chemical Co., St. Louis, MO). The stained cells
were analyzed by EPICS XL. (Coulter Electronics, Hialeah, FL).
 
In Vitro and In Vivo Colony Assay.
 
In vitro colony formation
in methylcellulose-containing semisolid medium was assayed as
described (27). Briefly, cultured or fresh BM cells were incubated
in 1 ml of culture medium containing 
 
a
 
-MEM (GIBCO BRL),
1.2% methylcellulose (Methocel A-4M; Muromachi Kagaku Ko-
gyo, Tokyo, Japan), 30% FCS (lot No. 1M1137; BioWhittaker),
1% deionized BSA (Sigma Chemical Co.), 50 
 
m
 
M 2-ME, 200 U/ml
IL-3, and 2 U/ml erythropoietin (Epo; Chugai Pharmaceutical
Co. Ltd., Tokyo, Japan). On the 7th d of culture, aggregates con-
sisting of 
 
.
 
40 cells were counted as a colony.
For CFU in spleen (CFU-s) assay, C57BL/6 mice were pur-
chased from Japan SLC Inc. (Shizuoka, Japan) and were used as
BM donors and recipients at 8–10 wk of age. Recipient mice
were maintained on acidified water (pH 2.5) 1 wk before the ir-
radiation (9.2 Gy) with a 
 
60
 
Co source, and donor cells were in-
jected the next day. 8 or 12 d thereafter, the number of colonies
that appeared in the recipient spleen was counted after fixation in
Bouin’s solution (38, 39).
 
Results
 
Distinct Types of Hematopoietic Cells Were Generated on
OP9 Stromal Cells Stimulated by EGF or bFGF.
 
Our pre-
vious study showed that the RPMI 1640/DMEM/F12–
based defined medium mSFO2 (Sanko Junyaku, Chiba,
Japan), which contains transferrin and insulin as the only
protein components, supported hematopoiesis on the stro-
mal cell lines ST2 and PA6 (40). To reduce the number of
factors present in this BM culture, we initialy examined
whether the stromal cell line OP9 (41), which was derived
from the M-CSF–deficient 
 
op
 
/
 
op
 
 mouse (42), can be used
for the BM culture with mSFO2 instead of ST2 or PA6,
which both express M-CSF. Moreover, because 2-ME is
essential for differentiation into B cell lineage, it was re-
moved from the original culture. Although OP9 cells could
not survive under serum deprivation, addition of either
rEGF or rbFGF solved this problem. While these in vitro
microenvironments supported the growth of fresh BM
cells, proliferation remained at a low level compared with
that of stromal cell–dependent hematopoiesis in the me-
dium-containing serum (see Fig. 2 
 
A
 
 and data not shown).
To enhance the proliferation of hematopoietic cells, we 
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Figure 1. Phenotypes of BM cells cultured under various conditions. Unfractionated BM cells (105) from C57BL/6 mouse were plated onto the OP9
stroma cells and cultured in mSFO2 containing 10% FCS (A), 10 ng/ml bFGF, and 100 ng/ml SCF (B), or 30 ng/ml EGF and 100 ng/ml SCF (C) in
60-mm culture dishes for 14 d. (D) Unfractionated BM cells (105) were plated onto OP9 stromal cells transformed with the v-erbB2 gene (OP9/erbB2)
in the mSFO2 plus SCF (100 ng/ml) for 21 d. Cultured BM cells were analyzed by May-Gruenwald-Giemsa staining (left) and by flow cytometry (right)
after staining with biotinylated anti–c-Kit (ACK4), FITC-conjugated Mac-1, and anti-B220 antibody. Biotinylated ACK4 was detected with streptavi-
din-PE. The numbers in each quadrant represent the percentages of gated bone marrow cells. Bar, 10 mm. 
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added the ligand for c-
 
kit
 
 (SCF) in the culture. The im-
provement was striking, as the cells extensively proliferated.
More marked was the finding that the cells proliferating in
the culture with EGF plus SCF retained an immature mor-
phology, having a large nucleus and azurophilic granules
(Fig. 1 
 
C
 
), while those in the culture with bFGF plus SCF
were heterogeneous, containing mature and immature my-
eloid cells (Fig. 1 
 
B
 
). In complete agreement with this mor-
phology, flow cytometry of the same cells showed that 98%
of the cultured cells were c-Kit
 
1
 
 in the EGF-containing
culture. More than 60% of the cells in the bFGF-contain-
ing culture were c-Kit
 
2
 
 (Fig. 1 
 
B
 
), while it contained more
Mac-1
 
high
 
 macrophages than the cultures with FCS (Fig. 1 
 
A
 
).
 
Cell Kinetics in the EGF-containing Culture.
 
The above re-
sults indicated that the OP9 stromal cell line with EGF and
SCF in the mSFO2-defined medium would provide a cul-
ture condition that allows the preferential growth of a sub-
set of hematopoietic stem cells. Next, we investigated how
long this selective proliferation of the hematopoietic stem
cells lasts under this culture condition. The expression of
c-Kit was used as a marker of the immature hematopoietic
cells. In this particular experiment, exponential cell prolif-
eration generating 
 
.
 
 a 1,000-fold increase in the cell num-
ber continued up to 40 d (Fig. 2 
 
A
 
). At the initial phase of
culture, the number of cultured cells increased 
 
z
 
100-fold
(Fig. 2 
 
A
 
), and the proportion of c-Kit
 
1
 
 cells increased to
80% in the 21-d culture (Fig. 2 
 
B
 
). Since normal BM con-
sists of 14% c-Kit
 
1
 
cells, their net increase over 21 d was
 
z
 
600-fold. Thereafter, however, the proportion of c-Kit
 
2
 
cells started to increase concomitantly with a decrease in
cell proliferation. These results suggested that this culture
condition is indeed selective for the c-Kit
 
1
 
 population dur-
ing the initial 3 wk, but it cannot block differentiation over
a longer period.
 
EGF Acts on OP9 Stromal Cells to Produce the Microenvi-
ronment Selective for Hematopoietic Cells.
 
Beug et al. have
demonstrated that TGF-
 
a
 
 acts on chicken erythroid pro-
genitors to maintain self-renewal without differentiation
(43). This suggests that EGF, which binds to the same re-
ceptor as TGF-
 
a
 
 (44), acts directly on murine hematopoie-
tic progenitors to augment their self-renewal. However,
we could not detect the direct binding of 
 
125
 
I-labeled EGF
to the cells proliferating under this condition (data not
shown). An alternative is that EGF acts on OP9 stromal
cells to create a microenvironment that is selective for the
self renewal of hematopoietic progenitors. To test this no-
tion, we established an OP9 subline (OP9/erbB2) that was
transduced with the v-
 
erb-B2
 
 gene containing a constitutive
active phosphorylation site in the cytoplasmic domain. This
cell line was maintained under serum-deprived conditions
without exogenous growth factors.
Unfractionated BM cells (10
 
5
 
) were cultured on OP9/
erbB2 in the presence of SCF, but without either EGF
or bFGF, and the cells recovered from the culture were
counted. As shown in Fig. 3 
 
A
 
, cell growth was exponen-
tial under this culture condition, although the growth rate
in this culture was slower than that in the culture with EGF.
Importantly, the morphological features of the proliferating
cells under this condition were similar to those cultured
with EGF (Fig. 1 
 
D
 
). This suggested that OP9 stromal
cells, when properly stimulated, can create a microenviron-
ment that is selective for c-Kit
 
1
 
 Mac-1
 
dull
 
 cells in the ab-
sence of exogenous growth factors.
 
Phenotype of the Cells Cultured with OP9/erbB2.
 
We an-
alyzed the surface phenotype of the cells proliferating under
this culture condition (OP9/erbB2 plus SCF). As shown in
Fig. 3 
 
B
 
, 
 
.
 
80% of the culture consisted of c-Kit
 
1
 
 imma-
ture cells. This c-Kit
 
1
 
 population was positive for common 
 
b
 
and common 
 
g
 
 chain expression, dull to positive for Mac-1,
Thy-1, and gp130 expression, and negative for c-FMS.
The clonogenic activity of this cell population was ana-
lyzed by means of in vitro colony-forming cell assays and
by transfer into irradiated mice (Table 1). Consistent with
the expression of the IL-3 receptor 
 
b
 
-chain in this cell
population, half of the cultured cells formed colonies in re-
sponse to IL-3 plus Epo. Since the frequency of CFU in
culture (CFU-c) in normal BM is 
 
z
 
1/140 (Table 1) and
the cell number increased 100-fold during 21 d of culture
(Fig. 3), the net increase of CFU-c was at least 7,000-fold.
In contrast to this high in vitro colony-forming ability, the
Figure 2. Growth kinetics and
c-Kit expression of BM cells cul-
tured on OP9 stroma cells with
mSFO2 containing EGF and
SCF. (A) Unfractionated BM
cells (105) from C57BL/6 mice
were plated on OP9 stroma cells
in mSFO2 containing 30 ng/ml
EGF (open circle) or 30 ng/ml
EGF plus 100 ng/ml SCF (filled
circle) in 60-mm culture dishes.
On the indicated days, the cul-
tured cells were harvested,
counted, analyzed for c-Kit ex-
pression, and replated on the
fresh OP9 layer. Each point rep-
resents the mean of triplicate cultures 6 SD. (B) Expression of c-Kit of the cultured cells harvested on the indicated days. Fresh BM (C57BL/6) and cul-
tured BM cells were stained with biotinylated anti–c-Kit (ACK4) antibody revealed by streptavidin-PE. Each staining profile (solid line) was superim-
posed onto that of the negative control (dashed line) stained with a biotinylated antibody against an irrelevant antigen. Percentage indicates the population
of c-Kit–positive cells. 
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frequency of CFU-s measured at days 8 and 12 after trans-
fer were 1/140 and 1/250, respectively. Thus, only a part
of this cell population maintained CFU-s activity. Since
frequencies of day 8 and day 12 CFU-s in normal BM cells
were 
 
z
 
1/5000, their net increases were 
 
z
 
3,600- and
2,000-fold, respectively. This indicates that while CFU-s
could expand under this culture condition, the cells with
long-term reconstituting activity were lost more rapidly
than the more mature progenitors. These results suggested
that the cells that were selected most preferentially under
our culture conditions represent short-term reconstituting
progenitors, probably CFU-c.
We next investigated whether this cell population, phe-
notypically representing CFU-c, preserves reactivity to
differentiation signals. In fact, almost all colonies formed in
response to IL-3
 
1
 
Epo contained mature myeloid and
monocytic cells (data not shown), suggesting that most cells
can readily differentiate. Since the culture with OP9 and
medium-containing serum provides conditions that favor
differentiation into mature hematopoietic cells (Fig. 1), we
investigated whether or not this cell population would re-
act to a shift from serum-deprived medium to medium
containing serum and 2-ME. As shown in Fig. 4, there was
a quick phenotypic shift, as the number of c-Kit
 
1
 
 cells de-
creased, whereas the number of c-Kit
 
2
 
Mac-1
 
1
 
 cells in-
creased to 45.8% 7 d after the shift. Thus, most cells main-
tained under our culture conditions were highly reactive to
this shift and readily gave rise to mature myelomonocytic
cells. At 14 d in culture, B220
 
1
 
 cells were generated, sug-
gesting that this cell population contained the progenitor
cells for B cell lineage. A small proportion of B220
 
2
 
IL-7R
 
1
cells appeared before the B2201 cells, which constituted
Figure 3. Growth kinetics of BM cells cultured on the OP9/erbB2
stromal layer and surface phenotype of recovered cells. (A) Unfraction-
ated BM cells (105) derived from C57BL/6 were plated on OP9/erbB2
stroma cells in mSFO2 supplemented with 100 ng/ml SCF. On the in-
dicated days, the cultured cells were harvested, counted, and replated
onto the fresh OP9/erbB2 stromal layer. (B) Cells harvested on the 21st d
of culture were analyzed by flow cytometry after staining with FITC-
conjugated Mac-1, anti-B220, TER119, CD4, CD8, biotinylated anti–c-Kit
(ACK4),Thy-1, anti–IL-7 receptor (A7R), anti–c-Fms (AFS98), anti-
gp130 (GP130), anti–common b (AIC2B), and anti–common g (TUGm3).
Biotinylated antibodies were detected with streptavidin-PE. The vertical
lines indicate the mean (left) and the maximal (right) fluorescence intensity
of cells stained with an isotype-matched control mAb.
Table 1. Frequency of Colony-forming Cells
Fresh BM per
5 3 104 cells
Cultured cells
per 103 cells Control
No. of CFCs
Factor: IL-3 and Epo 372.5 6 13.2 523.0 6 34.0 0*
No. of CFU-S
Day 8 11.2 6 2.5 7.0 6 2.0 0
Day 12 10.6 6 2.6 4.0 6 1.0 0.4 6 0.6
*This colony number was obtained by counting fresh BM cells (5 3
104) cultured in methylcellulose without IL-3 and Epo. The numbers in
the control line indicate colony numbers of those of nuclear cell counts
of BM in the control mice that were injected with PBS. The results
represent the mean 6 SE of triplicate samples.
Figure 4. Immediate differentiation of cultured c-Kit1Mac-1dull cell in
medium-containing serum. Unfractionated BM cells were cultured on
OP9/erbB2, as described in the legend to Fig. 3. 21 d later, the cells were
transferred onto a fresh OP9 stroma cell layer with medium-containing
serum (RPMI 1640 with 10% FCS and 5 3 1025 M 2-ME). The recov-
ered cells were analyzed after staining with FITC-conjugated Mac-1 and
biotinylated anti–c-Kit (ACK4), or FITC-conjugated anti-B220 and bio-
tinylated anti–IL-7 receptor (A7R) (A) before, (B) 7 d, or (C) 14 d after
the transfer. Biotinylated antibody was detected with streptavidin-PE.
The percentage of cells in each quadrant is shown in the top right-hand
corner of each panel.2306 Preferential Proliferation of Hematopoietic Progenitors
50% of the cells at the 14th d of culture. This suggested that
IL-7 receptor expression precedes the expression of B220
during B lineage differentiation.
Discussion
Our results demonstrated that the proliferation of a sub-
set of hematopoietic progenitors, most probably CFU-c,
can be selectively supported in vitro, whereas that of more
mature cells cannot. The optimal conditions for such selec-
tion were attained by using either the OP9 stromal cell
line, SCF, and EGF, or by using v-erbB2–transduced OP9
cells and SCF. Cells that were c-Kit1 Mac-1dull did not se-
lectively proliferate on the M-CSF–expressing stromal cell
lines PA6 or ST2 (40). Moreover, medium-containing se-
rum provided a microenvironment that favored hemato-
poietic differentiation, even if EGF was added to the cul-
ture (data not shown). The addition of 2-ME in mSFO2
promoted the proliferation of pre-B cells (c-Kit1 B2201
Mac-12) at 21 d of culture, even in the presence EGF and
SCF (data not shown). Therefore, the 2-ME–free, chemi-
cally defined medium and the M-CSF–deficient OP9 stro-
mal cell line are essential components of these culture con-
ditions. The addition of bFGF instead of EGF, however,
produced mature hematopoietic cells. This suggested that
an in vitro microenvironment formed by a uniform stromal
cell line in the absence of serum could be varied according
to the stimulation given to the stromal cells. Thus, the se-
lective proliferation of c-Kit1 Mac-1dull cells described here
appeared to be an outcome of a particular combination of
stromal cell molecules expressed by EGF-stimulated or
v-erbB2–transduced OP9. Nevertheless, these results indi-
cated that hematopoiesis is regulated, not only by mole-
cules directly acting on hematopoietic progenitors, but also
by those that stimulate stromal cell components.
It is totally obscure why the stimulation of OP9 cells by
EGF created a microenvironment that favored the self-
renewal of immature hematopoietic progenitors, whereas
bFGF could not. To examine whether more granulocyte
colony stimulating factor (G-CSF) or GM-CSF is pro-
duced by OP9 stimulation with bFGF than with EGF,
thereby generating mature hematopoietic cells, we tried to
inhibit these signals in the culture with OP9 stimulated by
bFGF. We inhibited G-CSF and GM-CSF signals, using
G-CSF receptor protein fused with human IgG1 protein that
saturates G-CSF (our unpublished data) and a neutralizing
mAb against GM-CSF (19). Even though we simulta-
neously inhibited both G-CSF and GM-CSF-signals, we
could not block the generation of differentiated cells com-
pletely in culture containing bFGF (data not shown). Thus,
it is very unlikely that the G-CSF or GM-CSF produced
by OP9 is responsible for the difference in the microenvi-
ronment created by EGF or bFGF stimulation.
Nevertheless, in complete agreement with the description
by Beug et al. (43) of chicken erythroid progenitors, our
results suggest that the balance between the self-renewal
and differentiation of nontransformed hematopoietic pro-
genitors can be regulated by a combination of the molecules
expressed in the microenvironment. This notion challenges
the widely held view that differentiated hematopoietic pro-
genitors, including committed progenitors, undergo only a
limited number of cell divisions. We are currently investi-
gating which molecules are induced specifically by EGF to
support the self-renewal of c-Kit1 Mac-1dull progenitors.
The most important feature of our procedure for enrich-
ing CFU-c, as compared with others, lies in the fact that
the hematopoietic progenitor cells spontaneously dominate
the culture. This is all that is required to simply culture un-
fractionated BM cells under the conditions described here.
However, stem cell clones cannot be established, because
the dominance of hematopoietic progenitors does not last
more than 30 d because of their eventual differentiation
into mature cells that do not proliferate. It is unclear
whether this limitation of our method in maintaining the
dominance of the immature progenitors is caused by the
limited life span of c-Kit1 Mac-1dull cells before terminal
differentiation or the inability of our culture conditions to
block their terminal differentiation. One line of evidence
suggests that this cell population is highly sensitive to the
differentiation cue. First, they are likely to represent short-
term reconstituting progenitors rather than the most imma-
ture stem cells, because 50% of them formed in vitro colo-
nies, whereas only 0.4% could form day 12 spleen colonies.
Second, the expression of Mac-1 in this population agrees
with the study of Heimfeld and Weissman (45, 46), who
found that Mac-1 is expressed by short-term–reconstituted
myeloid stem cells. Although our study and their cell-sort-
ing study did not address the differential capacity of indi-
vidual cells with this phenotype, Mac-1dull cells in our cul-
ture were by no means restricted to myeloid cell lineage,
because they also gave rise to B lineage cells (Fig. 4). In
fact, a recent study by Morrison et al. (47) has demon-
strated that the Thy-1low Mac-1dull population generated
cells of multiple lineages. Third, they are highly sensitive to
the differentiation cue, because they promptly gave rise to
mature blood cells both in vitro and in vivo. Thus, any
changes of the environment in the culture that could be in-
duced by stromal cell aging or even by an increase of he-
matopoietic cells themselves could alter the balance in favor
of differentiation of the progenitors. To develop long-term
stem cell cultures, it is important to determine how to
avoid such changes in the culture conditions.
A number of attempts have been made to establish a
stromal cell–dependent culture that selects hematopoietic
progenitors. The reports of Dexter and his colleagues have
shown that hematopoietic progenitors are spontaneously
selected from unfractionated BM cells on a v-src–trans-
duced stromal cell (48, 49). While this method is very sim-
ilar to ours, it has not become popular, probably because
the culture conditions are complex and include a high se-
rum concentration, as well as undefined stromal cell com-
ponents. In contrast, we used defined medium, only two
recombinant growth factors, and a cloned stromal cell line.
Palacios and Samaridis (50, 51) took the opposite approach2307 Takakura et al.
and added a cocktail of growth factors and carefully se-
lected FCS to a cultured stromal cell line to produce stem
cell clones. Although they claimed to be able to establish
progenitor clones, it has obvious problems in that (a) a
large number of cloned cells (.5 3 106) has to be trans-
ferred into the irradiated recipient to detect their differenti-
ation; (b) they could not form in vitro colonies, which are
important characteristics of normal hematopoietic progeni-
tors; and (c) only sorted cells can be used to initiate the cul-
ture. Compared with the reported methods, ours is simple
and reproducible, because it uses chemically defined condi-
tions and a cloned stromal cell line. However, it is not ef-
fective for isolating cell clones. The c-Kit1 Mac-1dull popu-
lation enriched in this culture readily differentiated in
response to various molecular cues. More than half of it re-
sponded to IL-3 to form colonies that contained mature
myelomonocytic cells. Moreover, when cultured on OP9
stromal cells together with FCS and 2-ME, they gave rise
to both myeloid and B2201 B lymphocytes.
In conclusion, though we still need to use the stromal
cell line of which the activity on the growth and differenti-
ation of CFU-c has not been fully defined, we are the first
to define the culture conditions that can enrich CFU-c. In
view of increasing interest in the clinical application of the
ex vivo expansion of hematopoietic stem cells, our results
are encouraging because we have showed that self-renewal
and differentiation of hematopoietic progenitors are some-
what controllable under defined culture conditions. Al-
though we determined that the removal of M-CSF and se-
rum was essential, while high levels of soluble SCF should
be included in the culture condition, other conditions cre-
ated by EGF-stimulated OP9 cells remain to be determined
so that this technology can be applied to human BM culture.
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